Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company’s development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”), a cli ...

Core Viewpoint - ASLAN Pharmaceuticals has been notified by Nasdaq of its non-compliance with listing requirements, leading to a decision not to request a hearing for continued listing [1][2]. Group 1: Nasdaq Compliance Issues - On July 9, 2024, Nasdaq informed ASLAN that it failed to meet the $1.00 bid price and $2.5 million stockholders' equity requirements for continued listing [1]. - The company was previously notified on January 5, 2024, that its American Depositary Shares (ADSs) had closed below the minimum $1.00 threshold for 30 consecutive business days [2]. - ASLAN was given a 180-day period until July 3, 2024, to regain compliance with the bid price requirement [2]. Group 2: Share Ratio Change - Effective July 3, 2024, ASLAN changed the ratio of its ordinary shares from one ADS representing 25 ordinary shares to one ADS representing 200 ordinary shares, resulting in a closing price above $1.00 per ADS [3]. - As of the press release date, the bid price for the company's ADSs had closed above the minimum $1.00 threshold for five consecutive business days [3]. Group 3: Company Overview - ASLAN Pharmaceuticals is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments, including eblasakimab for atopic dermatitis and farudodstat for alopecia areata [4]. - Eblasakimab is a potential first-in-class antibody targeting the IL-13 receptor, with positive topline data reported from a Phase 2b study [4]. - Farudodstat is being investigated as a potential first-in-class treatment for alopecia areata in a Phase 2a trial [4].

SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares ("ADSs") to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (2 ...

Investors might want to bet on ASLAN Pharmaceuticals Ltd. (ASLN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the s ...

Group 1 - A downtrend has been observed in ASLAN Pharmaceuticals Ltd. (ASLN), with the stock losing 8% over the past two weeks, but a hammer chart pattern formed in the last trading session suggests a potential trend reversal [1] - The hammer chart pattern indicates that the bears may have lost control over the price, signaling a possible bottom and exhaustion of selling pressure [1] - Rising optimism among Wall Street analysts regarding ASLN's future earnings enhances the prospects for a trend reversal [1] Group 2 - Over the last 30 days, the consensus EPS estimate for ASLN has increased by 5.2%, indicating that sell-side analysts expect better earnings than previously predicted [2] - ASLN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [2] - Stocks with a Zacks Rank of 1 or 2 typically outperform the market, and this rank serves as a strong timing indicator for potential improvements in a company's prospects [2]

Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations Results support further investigation of eblasakimab as a potential therapeutic option for COPD with potentially more effective blockade of Type-2 mediated inflammatory effects in lung tissue SAN MATEO, Calif. and ...

New positive data from an additional analysis of dupilumab-experienced patients treated with eblasakimab 400mg, weekly over 16 weeks further support the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumabData to be presented in a KOL event to be held Tuesday, May 7, 2024 at 8:00 am ET, register here SAN MATEO, Calif. and SINGAPORE, May 07, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused bioph ...

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab.The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of eblasakimab's po ...

ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinion Leader (KOL) Event, "Treatment Options for Atopic Dermatitis Pa ...

SAN MATEO, Calif. and SINGAPORE, April 24, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease has been accepted for a late breaking poster presentation at the American Thoracic Society International Conference 2024. The conference is taking place in San Diego, California, from ...